Upcoming biologic agents for the treatment of rheumatic diseases

The development of biologic agents has provided rheumatologists with a variety of new and effective treatment options. The success of early biologics, especially etanercept and infliximab for the treatment of rheumatoid arthritis, has spurred research into novel targets for the management of systemi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current opinion in rheumatology 2003-05, Vol.15 (3), p.226-263
Hauptverfasser:	Shanahan, Joseph C, Moreland, Larry W, Carter, Robert H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Biological Products - administration & dosage Biological Products - adverse effects Biological Therapy - standards Biological Therapy - trends Clinical Trials as Topic Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Etanercept Female Forecasting Humans Immunoglobulin G - administration & dosage Immunoglobulin G - adverse effects Infliximab Male Prognosis Receptors, Tumor Necrosis Factor - administration & dosage Rheumatic Diseases - diagnosis Rheumatic Diseases - drug therapy Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The development of biologic agents has provided rheumatologists with a variety of new and effective treatment options. The success of early biologics, especially etanercept and infliximab for the treatment of rheumatoid arthritis, has spurred research into novel targets for the management of systemic inflammatory and autoimmune diseases. In addition, existing biologics approved for use in other diseases, such as rituximab, are now under study for the treatment of new indications. This article reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents.
ISSN:	1040-8711 1531-6963
DOI:	10.1097/00002281-200305000-00009